Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Hologic Inc Stock Research

HOLX

70.13USD-0.08(-0.11%)Market Closed
Watchlist

Market Summary

USD70.13-0.08
Market Closed
-0.11%

HOLX Alerts

HOLX Stock Price

HOLX RSI Chart

HOLX Valuation

Market Cap

17.3B

Price/Earnings (Trailing)

35.77

Price/Sales (Trailing)

4.29

EV/EBITDA

16.73

Price/Free Cashflow

18.02

HOLX Price/Sales (Trailing)

HOLX Profitability

EBT Margin

22.44%

Return on Equity

14.21%

Return on Assets

7.97%

Free Cashflow Yield

5.55%

HOLX Fundamentals

HOLX Revenue

Revenue (TTM)

4.0B

Revenue Y/Y

-1.83%

Revenue Q/Q

-4.1%

HOLX Earnings

Earnings (TTM)

484.1M

Earnings Y/Y

-117.73%

Earnings Q/Q

-118.54%

Price Action

52 Week Range

59.7887.88
(Low)(High)

Last 7 days

-2.6%

Last 30 days

-7.0%

Last 90 days

-13.2%

Trailing 12 Months

11.4%

HOLX Financial Health

Current Ratio

4.41

Debt/Equity

0.55

Debt/Cashflow

0.64

HOLX Investor Care

Buy Backs (1Y)

1.53%

Diluted EPS (TTM)

1.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for HOLX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-20
Mohtashami Nanaz
acquired
-
-
745
-
2023-08-30
MACMILLAN STEPHEN P
gifted
-
-
-1,064,950
chairman, president and ceo
2023-06-30
Verstreken Jan
sold (taxes)
-26,072
80.97
-322
group president, international
2023-06-15
GARRETT SCOTT T
sold
-797,240
79.724
-10,000
-
2023-05-05
Mitchell Essex D
sold
-200,115
83.7302
-2,390
div. president, gyn surgical
2023-03-09
GARRETT SCOTT T
acquired
-
-
1,465
-
2023-03-09
Nawana Namal
acquired
-
-
1,465
-
2023-03-09
Wendell Amy McBride
acquired
-
-
1,465
-
2023-03-09
HANTSON LUDWIG
acquired
-
-
1,465
-
2023-03-09
CRAWFORD SALLY
acquired
-
-
1,465
-

1–10 of 50

Which funds bought or sold HOLX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Jefferies Group LLC
added
14,106
4,457,540
4,491,500
0.04%
2023-09-20
BARCLAYS PLC
added
15.24
6,379,000
47,188,000
0.03%
2023-09-12
Farther Finance Advisors, LLC
added
40.41
16,001
55,141
0.01%
2023-09-07
ST GERMAIN D J CO INC
new
-
14,575
14,575
-%
2023-09-05
Covenant Partners, LLC
new
-
291,654
291,654
0.10%
2023-09-01
Portside Wealth Group, LLC
new
-
366,392
366,392
0.07%
2023-08-24
Alberta Investment Management Corp
unchanged
-
20,705
6,208,940
0.06%
2023-08-23
HEADINVEST, LLC
reduced
-2.59
-77,857
775,788
0.17%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
0.59
266,562
29,116,800
0.28%
2023-08-22
NEW SOUTH CAPITAL MANAGEMENT INC
reduced
-7.05
-1,196,460
16,551,200
0.74%

1–10 of 49

Latest Funds Activity

Are funds buying HOLX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HOLX
No. of Funds

Schedule 13G FIlings of Hologic

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
t. rowe price investment management, inc.
9.5%
23,376,904
SC 13G
Feb 09, 2023
vanguard group inc
11.60%
28,519,496
SC 13G/A
Jan 24, 2023
blackrock inc.
9.6%
23,478,641
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
16.4%
41,296,661
SC 13G/A
Feb 10, 2022
vanguard group inc
10.94%
27,500,693
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 01, 2022
blackrock inc.
8.7%
21,888,278
SC 13G/A
Sep 10, 2021
fmr llc
-
0
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
15.2%
39,270,192
SC 13G/A
Feb 10, 2021
vanguard group inc
10.72%
27,548,047
SC 13G/A

Recent SEC filings of Hologic

View All Filings
Date Filed Form Type Document
Sep 22, 2023
8-K
Current Report
Sep 22, 2023
4
Insider Trading
Sep 22, 2023
3
Insider Trading
Sep 01, 2023
4
Insider Trading
Aug 01, 2023
10-Q
Quarterly Report
Jul 31, 2023
8-K
Current Report
Jul 05, 2023
4
Insider Trading
Jun 23, 2023
3
Insider Trading
Jun 20, 2023
4
Insider Trading

HOLX Fair Value

Loading...

Peers (Alternatives to Hologic)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
109.1B
19.5B
3.33% 38.88%
40.28
5.61
10.36% 30.30%
106.4B
31.6B
-2.70% -3.25%
29.34
3.37
1.57% -30.40%
103.0B
6.7B
-1.45% 53.92%
72.29
15.46
11.75% -0.66%
71.3B
19.0B
-4.73% 14.91%
44.09
3.79
0.46% -5.24%
42.2B
5.7B
-8.81% -18.03%
30.39
7.46
5.64% -4.53%
MID-CAP
9.5B
937.8M
-1.70% 33.64%
325.17
10.1
16.30% 250.21%
7.1B
616.6M
-9.39% -22.91%
29.21
11.56
69.52% 343.68%
5.0B
1.1B
-8.20% -13.76%
24
4.6
12.63% 50.85%
2.6B
452.1M
-18.55% -30.77%
-26.16
5.74
24.99% 24.09%
1.3B
790.3M
-28.57% -59.24%
-5.6
1.59
3.21% -1604.53%
SMALL-CAP
951.6M
780.7M
-5.71% -7.13%
-26.43
1.22
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
622.5M
162.9M
-20.52% -59.94%
-11.77
3.82
42.67% 12.82%
577.8M
162.2M
21.79% -40.17%
-6.87
3.56
9.71% 12.37%

Hologic News

Nasdaq
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know.
Nasdaq,
7 hours ago
Marketscreener.com
Marketscreener.com

Returns for HOLX

Cumulative Returns on HOLX

12.9%


10-Year Cumulative Returns

9.2%


7-Year Cumulative Returns

11.3%


5-Year Cumulative Returns

2.9%


3-Year Cumulative Returns

Risks for HOLX

What is the probability of a big loss on HOLX?

50%


Probability that Hologic stock will be more than 20% underwater in next one year

19.2%


Probability that Hologic stock will be more than 30% underwater in next one year.

18.5%


Probability that Hologic stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HOLX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Hologic was unfortunately bought at previous high price.

Drawdowns

Financials for Hologic

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-0.5%4,0384,0574,4664,8635,2265,3925,4945,6325,6635,3174,5363,7773,2953,3253,3873,3673,3153,2873,2583,2182,486
Gross Profit-8.0%2,0862,2682,6292,9973,3113,4633,6023,7963,9003,6642,9742,2281,5451,5241,1711,1711,3421,3341,7061,6971,276
Operating Expenses6.0%1,4091,3291,3681,3571,3721,4291,3661,3161,2261,1581,1081,1231,1601,1841,3101,2951,2811,2841,9381,9351,921
  S&GA Expenses-0.4%615618647630630621581561528489468485501541564565557554551545551
  R&D Expenses2.6%297290285283284288290276257243221223226232240232225218217219227
EBITDA-100.0%-1,1011,3921,7732,0402,4702,6642,8623,0472,8762,2231,494783757312------
EBITDA Margin-100.0%-0.27*0.31*0.36*0.39*0.46*0.48*0.51*0.54*0.54*0.49*0.40*0.24*0.23*0.09*------
Interest Expenses4.9%10710298.0095.0094.0093.0091.0094.0096.00102112117126134138141140140144149151
Earnings Before Taxes-26.0%6749101,2051,5881,8551,9442,1512,3612,5682,3981,7371,002262208-264-257-63.80-72.80-410-418741
EBT Margin-100.0%-0.22*0.27*0.33*0.36*0.36*0.39*0.42*0.45*0.45*0.38*0.27*0.08*0.06*-0.08*------
Net Income-35.7%4847539901,3021,5121,5521,7161,8702,0341,9031,3781,11149445184.00-203-29.60-10.60-419-111-161
Net Income Margin-100.0%-0.19*0.22*0.27*0.29*0.29*0.31*0.33*0.36*0.36*0.30*0.29*0.15*0.14*0.02*------
Free Cashflow-100.0%-9591,8152,055-2,6582,1482,2342,1911,7471,313798630579600593-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-1.2%9,3389,4499,2909,0719,3579,5159,2858,9208,5918,0447,5517,1966,8036,8226,3126,4426,5226,5256,9327,2317,091
  Current Assets3.0%4,3394,2114,0213,8623,9093,8813,5063,1692,4182,6622,5962,2221,9831,9371,6381,7931,5921,5111,4021,7231,595
    Cash Equivalents7.1%2,7652,5822,4412,3402,3752,2911,4211,170828816869701744800382602428401311667575
  Inventory-1.1%680688678624581526518501503456420395414401381445468443419384371
  Net PPE-0.9%493498494482490507554565551534515492456445452471470470473478462
  Goodwill0.0%3,2983,2973,2903,2373,2863,3173,3293,2824282,85732.002,6582,5932,5922,5942,5642,5662,5652,563--
  Current Liabilities2.8%9819559569381,0011,3051,2791,3271,4651,0361,0561,2391,3461,4811,0431,0701,0151,0451,0781,4031,235
    LT Debt, Current21.4%32.0026.0021.0015.008.0025624931346175.0075.00325566806302271262311319600525
    LT Debt, Non Current-0.3%2,7892,7982,8062,8082,8152,8132,8202,7122,6552,6722,6902,7142,7312,7492,7692,7842,7922,8002,8082,7052,722
Shareholder's Equity-2.2%5,1825,3015,0934,8764,9984,7934,5194,2193,8773,7953,2692,7072,2592,0912,2582,1162,2172,1602,3942,4292,450
  Retained Earnings-2.0%1,9662,0061,7881,6001,4821,253798298-30.50-298-918-1,573-2,068-2,206-2,302-2,688-2,565-2,659-2,386-2,494-2,544
  Additional Paid-In Capital0.5%6,1236,0926,0616,0436,0175,9975,9645,9665,9365,9275,8955,9055,8625,8285,7505,7705,7395,7235,6865,6715,647
Shares Outstanding-0.3%247248247-251252253-256258259-260263268-269269271-274
Minority Interest----------1.001.002.004.005.007.00------
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations0.2%9619591,8152,1262,4232,7552,2452,3302,3071,8671,433897702643659650634705668733667
  Share Based Compensation2.2%76.0074.0069.0067.0066.0066.0065.0065.0081.0085.0084.0083.0067.0061.0063.0062.0060.0064.0066.0065.00121
Cashflow From Investing-29.1%-128-99.30-73.80-206-217-965-1,453-1,329-1,424-702-145-141-84.50-81.00-195-280-307-301-299-195-195
Cashflow From Financing22.8%-442-573-726-756-668-318-245-529-798-1,150-798-659-299-162-393-431-468-605-712-404-487
  Buy Backs34.9%439325475542367555476410510322469654553604339200289335423276387

HOLX Income Statement

2023-07-01
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Millions
3 Months Ended9 Months Ended
Jul. 01, 2023
Jun. 25, 2022
Jul. 01, 2023
Jun. 25, 2022
Revenues:    
Product$ 799.1$ 837.1$ 2,522.9$ 3,408.7
Service and other185.3165.6562.2500.9
Revenues984.41,002.73,085.13,909.6
Costs of revenues:    
Product291.0266.3879.3907.0
Amortization, Cost of Goods Sold51.675.9159.3223.1
Impairment of intangible assets and equipment179.59.2179.59.2
Service and other94.8101.5295.8287.6
Gross profit367.5549.81,571.22,482.7
Operating expenses:    
Research and development72.665.1221.4207.4
Selling and marketing149.8152.3455.7471.0
General and administrative90.291.9299.5310.5
Amortization of acquired intangible assets7.111.221.933.2
Impairment of intangible assets and equipment44.30.044.30.0
Contingent consideration - fair value adjustments0.0(35.4)(12.4)(39.5)
Restructuring charges2.10.84.90.8
Operating expenses366.1285.91,035.3983.4
Income from operations1.4263.9535.91,499.3
Interest income32.52.484.63.6
Interest expense(27.7)(22.7)(83.0)(71.0)
Debt extinguishment loss0.00.00.0(0.7)
Other income (expense), net5.94.8(7.0)13.6
Income before income taxes12.1248.4530.51,444.8
Provision for income taxes52.620.0165.1261.5
Net income (loss)$ (40.5)$ 228.4$ 365.4$ 1,183.3
Net income (loss) per common share:    
Basic (in usd per share)$ (0.16)$ 0.91$ 1.48$ 4.70
Diluted (in usd per share)$ (0.16)$ 0.90$ 1.47$ 4.65
Weighted average number of shares outstanding:    
Basic (in shares)246,908250,756247,319251,943
Diluted (in shares)246,908253,093249,393254,273

HOLX Balance Sheet

2023-07-01
Consolidated Balance Sheets - USD ($)
$ in Millions
Jul. 01, 2023
Sep. 24, 2022
Current assets:  
Cash and cash equivalents$ 2,765.0$ 2,339.5
Accounts receivable, less reserves686.8617.6
Inventories680.1623.7
Prepaid Expense, Current173.7232.2
Prepaid Income Taxes-Current33.749.0
Total current assets4,339.33,862.0
Property, plant and equipment, net493.3481.6
Intangible assets, net940.11,280.6
Goodwill3,298.23,236.5
Other assets267.0210.5
Total assets9,337.99,071.2
Current liabilities:  
Current portion of long-term debt31.815.0
Accounts payable180.6197.7
Accrued expenses533.1535.3
Deferred revenue232.9186.5
Finance lease obligations2.93.2
Total current liabilities981.3937.7
Long-term debt, net of current portion2,789.32,808.4
Finance lease obligations, net of current portion16.218.0
Deferred Income Tax Liabilities, Net19.490.8
Deferred revenue, net of current portion13.79.4
Other long-term liabilities336.0330.7
Stockholders’ equity:  
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued0.00.0
Common stock, $0.01 par value – 750,000 shares authorized; 299,932 and 298,533 shares issued, respectively3.03.0
Additional paid-in-capital6,122.56,042.6
Retained earnings1,965.71,600.3
Treasury stock, at cost – 54,990 and 51,401 shares, respectively(2,795.6)(2,531.5)
Accumulated other comprehensive loss(113.6)(238.2)
Total stockholders’ equity5,182.04,876.2
Total liabilities and stockholders’ equity$ 9,337.9$ 9,071.2
Stephen P. MacMillan
6700
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.